Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

01-12-2021 | NSCLC | Primary research

ARHGAP10 inhibits the epithelial–mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3β signaling pathway

Authors: Lan-Lan Lin, Fan Yang, Dong-Huan Zhang, Cong Hu, Sheng Yang, Xiang-Qi Chen

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Rho GTPase activating protein 10 (ARHGAP10) has been implicated as an essential element in multiple cellular process, including cell migration, adhesion and actin cytoskeleton dynamic reorganization. However, the correlation of ARHGAP10 expression with epithelial–mesenchymal transition (EMT) in lung cancer cells is unclear and remains to be elucidated. Herein, we investigated the relationship between the trait of ARHGAP10 and non-small cell lung cancer (NSCLC) pathological process.

Methods

Immunohistochemistry was conducted to evaluate the expression of ARHGAP10 in NSCLC tissues. CCK-8 assays, Transwell assays, scratch assays were applied to assess cell proliferation, invasion and migration. The expression levels of EMT biomarkers and active molecules involved in PI3K/Akt/GSK3β signaling pathway were examined through immunofluorescence and Western blot.

Results

ARHGAP10 was detected to be lower expression in NSCLC tissues compared with normal tissues from individuals. Moreover, overexpression of ARHGAP10 inhibited migratory and invasive potentials of A549 and NCI-H1299 cells. In addition, ARHGAP10 directly mediated the process of EMT via PI3K/Akt/GSK3β pathway. Meanwhile, activation of the signaling pathway of insulin-like growth factors-1 (IGF-1) reversed ARHGAP10 overexpression regulated EMT in NSCLC cells.

Conclusion

ARHGAP10 inhibits the epithelial–mesenchymal transition in NSCLC via PI3K/Akt/GSK3β signaling pathway, suggesting agonist of ARHGAP10 may be an optional remedy for NSCLC patients than traditional opioids.
Literature
1.
Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(1):9–31.PubMedPubMedCentralCrossRef
2.
Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed progress in second-line advanced non–small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol. 2016;34(14):1676–88.PubMedCrossRef
3.
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–74.PubMedCrossRef
4.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.CrossRefPubMed
5.
van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet. 2016;4(9):749–61.
6.
Bigarella CL, Vieira Ferro KP, Barcellos KSA, Martins-de-Souza D, Traina F, Novello JC, Olalla Saad ST, Archangelo LF. Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. FEBS Lett. 2012;586(19):3522–8.PubMedCrossRef
7.
Zhang L, Wrana JL. Regulation of Rho GTPases from the lateral sides of migrating cells. Small GTPases. 2018;9(4):345–8.PubMedCrossRef
8.
Sanchez Bassères D, Vedelago Tizzei E, Duarte AA, Costa FF, Teresinha Olalla Saadsta S. ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. Biochem Biophys Res Co. 2002;294(3):579–85.CrossRef
9.
Barcellos KSA, Bigarella CL, Wagner MV, Vieira KP, Lazarini M, Langford PR, Machado-Neto JA, Call SG, Staley DM, Chung JY, et al. ARHGAP21 protein, a new partner of α-tubulin involved in cell-cell adhesion formation and essential for epithelial–mesenchymal transition. J Biol Chem. 2013;288(4):2179–89.PubMedCrossRef
10.
Sousa S, Cabanes D, Archambaud C, Colland F, Lemichez E, Popoff M, Boisson-Dupuis S, Gouin E, Lecuit M, Legrain P, et al. ARHGAP10 is necessary for α-catenin recruitment at adherens junctions and for Listeria invasion. Nat Cell Biol. 2005;7(10):954–60.PubMedCrossRef
11.
Hui L, Su Y, Ye T, Liu Z, Tian Q, He C, Zhao Y, Chen P, Wang X, Han W, et al. Self-Sterilizing and regeneratable microchip for the precise capture and recovery of viable circulating tumor cells from patients with cancer. ACS Appl Mater Inter. 2018;10(1):207–18.CrossRef
12.
Yeung KT, Yang J. Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39.PubMedCrossRef
13.
Nurwidya F, Takahashi F, Murakami A, Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 2012;44(3):151–6.PubMedPubMedCentralCrossRef
14.
Thiede BR, Corwin JT. Permeation of fluorophore-conjugated phalloidin into live hair cells of the inner ear is modulated by P2Y receptors. J Assoc Res Otolaryngol JARO. 2014;15(1):13–30.PubMedCrossRef
15.
Mair GR, Halton DW, Maule AG. The neuromuscular system of the sheep tapeworm Moniezia expansa. Invert Neurosci IN. 2020;20(4):17.PubMedCrossRef
16.
Pei XD, Yao HL, Shen LQ, Yang Y, Lu L, Xiao JS, Wang XY, He ZL, Jiang LH. α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway. Eur J Pharmacol. 2020;883:173355.PubMedCrossRef
17.
18.
19.
Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ. The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells. Oncol Lett. 2017;14(4):4613–8.PubMedPubMedCentralCrossRef
20.
Roshan MK, Soltani A, Soleimani A, Kahkhaie KR, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial–mesenchymal transition (EMT) process. Biochimie. 2019;165:229–34.CrossRef
21.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.PubMedCrossRef
22.
Zhou Y, Hua Z, Zhu Y, Wang L, Chen F, Shan T, Zhou Y, Dai T. Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway. Cancer Cell Int. 2020;20:225.PubMedPubMedCentralCrossRef
23.
He Y, Northey JJ, Pelletier A, Kos Z, Meunier L, Haibe-Kains B, Mes-Masson A, Côté J, Siegel PM, Lamarche-Vane N. The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. Oncogene. 2017;36(24):3490–503.PubMedPubMedCentralCrossRef
24.
Chen D, Li Y, Zhang X, Wu H, Wang Q, Cai J, Cui Y, Liu H, Lan P, Wang J, et al. Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation. Oncogene. 2019;38(37):6429–44.PubMedPubMedCentralCrossRef
25.
Tian T, Chen ZH, Zheng Z, Liu Y, Zhao Q, Liu Y, Qiu H, Long Q, Chen M, Li L, et al. Investigation of the role and mechanism of ARHGAP5-mediated colorectal cancer metastasis. Theranostics. 2020;10(13):5998–6010.PubMedPubMedCentralCrossRef
26.
Dai B, Zhang X, Shang R, Wang J, Yang X, Zhang H, Liu Q, Wang D, Wang L, Dou K. Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma. Cell Commun Signal. 2018;16(1):99.PubMedPubMedCentralCrossRef
27.
Lee D. miR-769-5p is associated with prostate cancer recurrence and modulates proliferation and apoptosis of cancer cells. Exp Ther Med. 2021;21(4):335.PubMedPubMedCentralCrossRef
28.
Gong H, Chen X, Jin Y, Lu J, Cai Y, Wei O, Zhao J, Zhang W, Wen X, Wang Y, et al. Expression of ARHGAP10 correlates with prognosis of prostate cancer. Int J Clin Exp Pathol. 2019;12(10):3839–46.PubMedPubMedCentral
29.
Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56–68.PubMedCrossRef
30.
Bigarella CL, Borges L, Costa FF, Saad STO. ARHGAP21 modulates FAK activity and impairs glioblastoma cell migration. Biochimica et Biophysica Acta BBA Mol Cell Res. 2009;1793(5):806–16.CrossRef
31.
Luo N, Guo J, Chen L, Yang W, Qu X, Cheng Z. ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis. 2016;7(3):e2157.PubMedPubMedCentralCrossRef
32.
Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 2020;262:118513.PubMedCrossRef
33.
Liu L, Xie D, Xie H, Huang W, Zhang J, Jin W, Jiang W, Xie D. ARHGAP10 inhibits the proliferation and metastasis of CRC cells via blocking the activity of RhoA/AKT signaling pathway. Oncotargets Ther. 2019;12:11507–16.CrossRef
34.
Yeung CY, Taylor SH, Garva R, Holmes DF, Zeef LA, Soininen R, Boot-Handford RP, Kadler KE. Arhgap28 is a RhoGAP that inactivates RhoA and downregulates stress fibers. PLoS ONE. 2014;9(9):e107036.PubMedPubMedCentralCrossRef
35.
Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci (Landmark Ed). 2011;16:2561–71.CrossRef
36.
Wang J, Luo J, Huang W, Liu C, Zeng D, Liu H, Qu X, Liu C, Xiang Y, Qin X. Increased intracellular Cl concentration by activating FAK promotes airway epithelial BEAS-2B cells proliferation and wound healing. Arch Biochem Biophys. 2020;680:108225.PubMedCrossRef
37.
Uchida S, Saimi M, Li ZL, Miyaso H, Nagahori K, Kawata S, Omotehara T, Ogawa Y, Itoh M. Effects of phosphorylated estrogen receptor alpha on apoptosis in human endometrial epithelial cells. Anat Sci Int. 2020;95(2):240–50.PubMedCrossRef
38.
Long XS, Liao ST, Wen P, Zou YX, Liu F, Shen WZ, Hu TG. Superior hypoglycemic activity of mulberry lacking monosaccharides is accompanied by better activation of the PI3K/Akt and AMPK signaling pathways. Food Funct. 2020;11(5):4249–58.PubMedCrossRef
39.
Lu Y, Lei S, Wang N, Lu P, Li W, Zheng J, Giri PK, Lu H, Chen X, Zuo Z, et al. Protective effect of minocycline against ketamine-induced injury in neural stem cell: involvement of PI3K/Akt and Gsk-3 beta pathway. Front Mol Neurosci. 2016;9:135.PubMedPubMedCentralCrossRef
40.
García de Herreros A, Duñach M. Intracellular signals activated by canonical Wnt ligands independent of GSK3 inhibition and β-catenin stabilization. Cells Basel. 2019;8(10):1148.CrossRef
41.
Wen SY, Chen YY, Deng CM, Zhang CQ, Jiang MM. Nerigoside suppresses colorectal cancer cell growth and metastatic potential through inhibition of ERK/GSK3β/β-catenin signaling pathway. Phytomedicine Int J Phytother Phytopharmacol. 2019;57:352–63.CrossRef
42.
Zhang H, Rong X, Wang C, Liu Y, Lu L, Li Y, Zhao C, Zhou J. VBP1 modulates Wnt/β-catenin signaling by mediating the stability of the transcription factors TCF/LEFs. J Biol Chem. 2020;295:16826–39.PubMedCrossRef
Metadata
Title
ARHGAP10 inhibits the epithelial–mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3β signaling pathway
Authors
Lan-Lan Lin
Fan Yang
Dong-Huan Zhang
Cong Hu
Sheng Yang
Xiang-Qi Chen
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02022-7

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors

Primary research

Circular RNA hsa_circ_0003288 induces EMT and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma

Primary Research

Identification of a VHL gene mutation in atypical Von Hippel-Lindau syndrome: genotype–phenotype correlation and gene therapy perspective

Primary research

BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

Primary research

Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas

Review

MicroRNAs and angiogenesis: a new era for the management of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits